Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a heterogeneous group of aggressive malignancies characterized by the uncontrolled proliferation of leukemia cells. Among patients with AML younger than 60 years, the complete remission (CR) rate is approximately 60% and the 5-year overall survival (OS) is approximately 40% after intensive chemotherapy and progressive, supportive treatment [1]. Unfortunately, the median age of patients with AML is approximately 65 years [2] and the CR and long-term disease-free survival rates remain low in this population.

Source: Experimental Hematology - September 9, 2018 Category: Hematology Authors: Xin Li, Lan Xu, Xianfu Sheng, Jiayi Cai, Jia Liu, Tingyu Yin, Fei Xiao, Fangyuan Chen, Hua Zhong Source Type: research